Stereotactic arrhythmia radiotherapy (STAR) resulted in a ≥50% reduction in treated VT-episodes in 67% (4/6) of patients with therapy-refractory ventricular tachycardia.
Does stereotactic arrhythmia radiotherapy reduce treated VT-episodes in patients with therapy-refractory ventricular tachycardia?
Stereotactic arrhythmia radiotherapy (STAR) appears safe and effectively reduces treated VT-episodes in patients with therapy-refractory ventricular tachycardia.
AIMS: Stereotactic arrhythmia radiotherapy (STAR) is suggested as potentially effective and safe treatment for patients with therapy-refractory ventricular tachycardia (VT). However, the current prospective knowledge base and experience with STAR is limited. In this study we aimed to prospectively evaluate the efficacy and safety of STAR. METHODS AND RESULTS: The StereoTactic Arrhythmia Radiotherapy in the Netherlands no.1 was a pre-post intervention study to prospectively evaluate efficacy and safety of STAR. In patients with therapy-refractory VT, the pro-arrhythmic region was treated with a 25 Gy single radiotherapy fraction. The main efficacy measure was a reduction in the number of treated VT-episodes by ≥50%, comparing the 12 months before and after treatment (or end of follow-up, excluding a 6-week blanking period). The study was deemed positive when ≥50% of patients would meet this criterion. Safety evaluation included left ventricular ejection fraction, pulmonary function, and adverse events. Six male patients with an ischaemic cardiomyopathy were enrolled, and median age was 73 years (range 54-83). Median left ventricular ejection fraction was 38% (range 24-52). The median planning target volume was 187 mL (range 93-372). Four (67%) patients completed the 12-month follow-up, and two patients died (not STAR related) during follow-up. The main efficacy measure of ≥50% reduction in treated VT-episodes at the end of follow-up was achieved in four patients (67%). The median number of treated VT-episodes was reduced by 87%. No reduction in left ventricular ejection fraction or pulmonary function was observed. No treatment related serious adverse events occurred. CONCLUSIONS: STAR resulted in a ≥ 50% reduction in treated VT-episodes in 4/6 (67%) patients. No reduction in cardiac and pulmonary function nor treatment-related serious adverse events were observed during follow-up. CLINICAL TRIAL REGISTRATION: Netherlands Trial Register-NL7510.
Ree et al. (Tue,) conducted a other in Therapy-refractory ventricular tachycardia (n=6). Stereotactic arrhythmia radiotherapy (STAR) vs. Pre-treatment baseline (12 months prior) was evaluated on Reduction in the number of treated VT-episodes by ≥50%, comparing the 12 months before and after treatment. Stereotactic arrhythmia radiotherapy (STAR) resulted in a ≥50% reduction in treated VT-episodes in 67% (4/6) of patients with therapy-refractory ventricular tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: